Octahedral metal (III) polypyridyl complexes and their use in prevention and treatment of cancer

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent describes a new class of octahedral metal(III) polypyridyl complexes, specifically based on rhodium or iridium combined with various polypyridyl ligands and halogen or pseudohalogen groups. These compounds demonstrate potent cytotoxic effects against cancer cells, especially breast and colorectal cancers, and are claimed to surpass current metal-based drugs like cisplatin in therapeutic effectiveness. The invention covers the chemical synthesis of these complexes, their pharmaceutical formulations, and their application in preventing and treating cancer and metastasis, with a range of possible dosage forms and delivery mechanisms.

Use CasesContent extracted from patent full text and abstract with AI.

• Treatment of breast cancer in clinical oncology
• Treatment of colorectal cancer
• Therapeutic intervention for metastatic cancers
• Potential application for leukemia and other neoplasias
• Development of new anticancer drugs with improved activity and potentially lower side effects
• Creation of pharmaceutical formulations for oral, injectable, or topical cancer therapies

BenefitsContent extracted from patent full text and abstract with AI.

• Demonstrate significantly higher cytotoxicity against cancer cells than existing drugs such as cisplatin, possibly leading to improved efficacy
• Effective against a range of tumor types, including breast, colorectal, and leukemic cancers
• Can be formulated into various pharmaceutical forms for flexible administration routes (oral, injectable, topical, etc.)
• Potential for fewer side effects or resistance issues compared to traditional metal-based anticancer drugs
• Incorporation into modern drug delivery systems such as liposomes or nanoparticles enhances targeted delivery and reduces off-target toxicity
• Possibility to tailor chemical structure (via ligand or substituent variation) for optimized performance and solubility

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The present invention relates to new octahedral metal (III) polypyridyl complexes of general formula I €ƒ€ƒ€ƒ€ƒ€ƒ€ƒ€ƒ€ƒ Me(hal) 3 (sol)(pp)€ƒ€ƒ€ƒ€ƒ€ƒ(I) where Me represents rhodium or iridium hal is a halogenide selected from the group consisting of chlorine, bromine, fluorine and iodine or a pseudohalogenide selected from the group consisting of SCN, NCO or N 3 , sol is a solvent selected from the group consisting of DMSO, H 2 O, CH 3 OH, DMF and CH 3 CN and pp is a polypyridyl ligand selected from the group constisting of 2,2'-bipyridine (bpy), 1,10-phenanthroline (phen), dipyrido[3,2-f:2',3'-h]quinoxaline (dpq), dipyrido[3,2-a:2',3'-c]phenazine (dppz) and benzo[i]dipyrido[3,2-a:2',3'-c]phenazine (dppn), optionally substituted with one or more of the substituents selected from the group constisting of hydroxy, -COOR, -SO 3 H, -CHO, -CH 3 , -CF 3 , -OCH 3 , -OC 2 H 5 , -NO 2 , -CN, -NH 2 , phenyl and halogenide, wherein R = H, -CH 3 or -C 2 H 5 , and their use in prevention and treatment of cancer.